Construction of an Epithelial-Mesenchymal Transition-Related Model for Clear Cell Renal Cell Carcinoma Prognosis Prediction

Figure 5

Box plot of estimated IC50 values for (a) axitinib, (b) bortezomib, (c) cisplatin, (d) gefitinib, (e) sorafenib, (f) sunitinib, (g) temsirolimus, and (h) Vinblastine in low and high risk-score groups.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)